Verici Dx completes analytical validation on two assays
15th Feb 2022 14:28
(Sharecast News) - Clinical diagnostics developer Verici Dx announced on Tuesday that its two lead in-vitro diagnostic assays, 'Clarava' and 'Tuteva', had completed analytical validation under the CLIA requirements, meeting criteria for robust assay performance.
Read moreVerici Dx enters collaboration with Nasdaq-listed Illumina
5th Jan 2022 12:54
(Sharecast News) - Organ transplant clinical diagnosis developer Verici Dx announced a collaboration with Nasdaq-listed Illumina on Wednesday, to expedite the operational launch of data analysis processing and the predictive artificial intelligence component of its products using early access to Illumina's new software platform ICA.
Read moreVerici granted 'fundamental' codes for tests in US market
4th Jan 2022 16:05
(Sharecast News) - Organ transplant diagnostics company Verici Dx has been granted 'CPT' proprietary laboratory analyses (PLA) codes for both its 'Clarava' and 'Tuteva' tests by the American Medical Association (AMA), it announced on Tuesday.
Read moreVerici enrols patients for multi-centre study ahead of forecast
31st Aug 2021 12:32
(Sharecast News) - Organ transplant diagnostics developer Verici Dx announced on Tuesday that patient enrolment for a multi-centre observational clinical validation study for its lead products had concluded ahead of management expectations.
Read more